[Research progress on mesenchymal stem cells and their extracellular vesicles in immune thrombocytopenia].

Authors

Wuxia Yang, Muhua Chen, Caiyan Jia, Xin Yu, Aidi Wang, Baoshan Liu

Published in

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. Volume 42. Issue 11. Pages 1025-1031.

Abstract

Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder, of which conventional therapeutic approaches are often associated with a high relapse rate. Studies have demonstrated abnormalities in both the quantity and function of bone marrow-derived mesenchymal stem cells (BM-MSC) in ITP patients. In contrast, the administration of exogenous MSC has been shown to exert therapeutic effects through mechanisms such as immune modulation and inhibition of autoantibody production. In recent years, extracellular vesicles derived from MSCs (MSC-EV) have gained considerable attention as a promising cell-free treatment strategy. MSC-EV can deliver a wide range of bioactive molecules and offer benefits such as low immunogenicity and high stability, having demonstrated significant efficacy in animal models of ITP. In summary, restoring BM-MSC function in ITP patients and utilizing exogenous MSC or MSC-EV may provide novel directions for the treatment of ITP.

PMID:
43009332
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.